RDHL.TA - RedHill Biopharma Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
396.00
+6.70 (+1.72%)
At close: 5:24PM IDT
Stock chart is not supported by your current browser
Previous Close389.30
Open389.30
Bid472.30 x 400800
Ask396.00 x 100
Day's Range375.60 - 400.00
52 Week Range157.00 - 403.00
Volume418,257
Avg. Volume271,891
Market Cap845.218M
Beta0.15
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire14 days ago

    RedHill Biopharma Announces Allowance of Two New RHB-104 Patents Ahead of Top-Line Phase III Results for Crohn’s Disease

    TEL-AVIV, Israel and RALEIGH, N.C., July 02, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal (GI) diseases, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) and an Intention to Grant from the European Patent Office (EPO) for two new patents covering RHB-104, expected to be valid until at least February 5, 2029, once granted. The development of RHB-104 for Crohn’s disease is based on the hypothesis that Crohn’s disease is caused by Mycobacterium avium subspecies paratuberculosis (MAP) infection in susceptible patients.

  • GlobeNewswire18 days ago

    RedHill Biopharma Announces U.S. Co-Promotion Agreement with Napo Pharmaceuticals for HIV/AIDS Anti-Diarrheal Drug Mytesi®

    RedHill has been granted the exclusive right to co-promote Mytesi ® in the U.S. to certain gastroenterologists and primary care physicians for the approved indication in people living with HIV/AIDS by ...

  • GlobeNewswire2 months ago

    RedHill Biopharma to Present Positive Phase II Results of BEKINDA® for IBS-D at Digestive Disease Week 2018

    TEL-AVIV, Israel and RALEIGH, N.C., May 30, 2018-- RedHill Biopharma Ltd., a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...

  • GlobeNewswire2 months ago

    RedHill Biopharma Announces New U.S. Patent for its Experimental Ebola Therapy

    TEL-AVIV, Israel and RALEIGH, N.C., May 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering RedHill’s proprietary experimental therapy for the treatment of Ebola virus disease. As part of RedHill’s research collaboration with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH), the Company successfully completed a proof-of-concept study to evaluate its proprietary experimental therapy for the treatment of Ebola virus disease.

  • GlobeNewswire2 months ago

    RedHill Biopharma to Host Investor Webcast on RHB-104 for Crohn’s Disease on May 15

    TEL-AVIV, Israel and RALEIGH, N.C., May 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases, today announced that it will host a webcast for the investment community on RHB-104 and the first Phase III study with RHB-104 for Crohn’s disease (MAP US), tomorrow, Tuesday, May 15, at 8:00 a.m. EDT. Members of RedHill’s executive team will be joined by key opinion leaders who will discuss RHB-104, the MAP US study, Crohn’s disease, the current treatment landscape and potential market.

  • GlobeNewswire2 months ago

    RedHill Biopharma Reports First Quarter 2018 Financial Results

    Top-line results from Phase III study with RHB-104 for Crohn’ s disease expected in approximately 3 months Top-line results from confirmatory Phase III study with TALICIA ® for H. pylori infection expected ...

  • GlobeNewswire2 months ago

    RedHill Biopharma Announces Last Patient Assessed for Primary Endpoint in RHB-104 Phase III Study for Crohn’s Disease

    TEL-AVIV, Israel and RALEIGH, N.C., May 07, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal diseases, today announced that the last patient enrolled in the first Phase III study with RHB-104 for Crohn’s disease (the MAP US study) has completed 26 weeks of treatment for primary endpoint evaluation. Top-line results are expected to be announced in approximately three months.

  • GlobeNewswire2 months ago

    RedHill Biopharma Announces Enrollment of 300th Patient in Confirmatory Phase III Study with TALICIA® for H. pylori Infection

    Approximately 70% of the planned total of 444 patients have been enrolled in the ongoing confirmatory U.S. Phase III study with TALICIA ® for H. pylori infection RedHill expects to complete enrollment ...

  • GlobeNewswire2 months ago

    RedHill Biopharma to Host First Quarter 2018 Financial Results Conference Call on May 8, 2018

    TEL-AVIV, Israel and RALEIGH, N.C., May 01, 2018-- RedHill Biopharma Ltd., a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary ...

  • GlobeNewswire8 months ago

    RedHill Biopharma Announces Closing of Public Offering of its American Depositary Shares

    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 13, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical ...

  • GlobeNewswire8 months ago

    RedHill Biopharma Reports 2017 Third Quarter Financial Results

    RedHill maintains a debt-free balance sheet with $39.6 million in cash1 at the end of the third quarter of 2017 In addition, an underwritten public offering of the Company`s American Depositary Shares ...